Timely synthetic support for medicinal chemists.

In recent years, there have been significant developments made in the way new drugs are being discovered and developed. Such changes are driven by new technologies that have expanded the opportunities to prepare and screen large libraries of compounds in a rapid time frame by the use of high-throughput synthesis and screening techniques [1-3]. These strategies are driven by the need to shorten time lines for bringing discovery leads to the market [4,5]. As a result, the role and needs of synthetic chemistry in the discovery and development of new therapeutic agents has been altered [6]. This paper will explore the roles of synthetic chemists and how pharmaceutical companies respond to the evolving needs of synthetic chemistry challenges in their discovery and development programs.

[1]  W. Curatolo,et al.  Physical chemical properties of oral drug candidates in the discovery and exploratory development settings , 1998 .

[2]  S. Venkatesh,et al.  Role of the development scientist in compound lead selection and optimization. , 2000, Journal of pharmaceutical sciences.

[3]  I. Hughes,et al.  Techniques for analysis and purification in high-throughput chemistry. , 2001, Current opinion in chemical biology.

[4]  Hans-Jürgen Federsel,et al.  Facing chirality in the 21st century: Approaching the challenges in the pharmaceutical industry. , 2003, Chirality.

[5]  David J W Grant,et al.  A timely re-examination of drug polymorphism in pharmaceutical development and regulation. , 2004, Advanced drug delivery reviews.

[6]  H -J. Federsel.  Drug discoverers -you need us! , 2001, Drug discovery today.

[7]  Andrew T Merritt.  Uptake of new technology in lead optimization for drug discovery , 1998 .

[8]  Jack Elands.  The Evolution of Laboratory Automation , 2001 .

[9]  D. Ritchie,et al.  The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. , 2001, Current topics in medicinal chemistry.

[10]  The dilemma of process development. , 2002, Drug discovery today.

[11]  P. Reider,et al.  Stereoselective synthesis from a process research perspective. , 2002, Drug discovery today.

[12]  W. Tong,et al.  Impact of solid state properties on developability assessment of drug candidates. , 2004, Advanced drug delivery reviews.

[13]  Increasing the efficiency of small-molecule drug discovery. , 2003, Drug discovery today.

[14]  R. Labaudinière.  RPR's approach to high-speed parallel synthesis for lead generation , 1998 .

[15]  Hird.  Automated synthesis: new tools for the organic chemist. , 1999, Drug discovery today.

[16]  A Golebiowski,et al.  Lead compounds discovered from libraries. , 2001, Current opinion in chemical biology.

[17]  Coates,et al.  Successful implementation of automation in medicinal chemistry. , 2000, Drug discovery today.

[18]  Federsel.  Building bridges from process R&D: from a customer-supplier relationship to full partnership. , 2000, Pharmaceutical science & technology today.

[19]  R. Goodnow.  Current practices in generation of small molecule new leads , 2001, Journal of cellular biochemistry. Supplement.

[20]  Hans-Jürgen Federsel,et al.  A guide to drug discovery: Logistics of process R&D: transforming laboratory methods to manufacturing scale , 2003, Nature Reviews Drug Discovery.

[21]  W. Goetzinger,et al.  High-throughput techniques for compound characterization and purification. , 2001, Current opinion in drug discovery & development.